Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Paraproteinemias 1

Interventions

venetoclax 6ibrutinib 4pirtobrutinib 2Sirolimus 2Rituximab 2Mycophenolic Acid 2Cyclosporine 2Cyclophosphamide 2zanubrutinib 1pembrolizumab 1loncastuximab tesirine 1fludarabine phosphate 1carfilzomib 1acalabrutinib 1Whole-Body Irradiation 1Tacrolimus 1Specimen Handling 1Rifaximin 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1Melphalan 1Magnetic Resonance Spectroscopy 1Etoposide 1Dexamethasone 1Cyclosporins 1Calcium Dobesilate 1CT-P10 1Busulfan 1Biopsy 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Waldenstrom Macroglobulinemia × Rifaximin × 30 days × Clear all
NCT03820817 2026-05-26

Rifaximin in Patients With Monoclonal Gammopathy

Emory University

Phase 1 Completed
50 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡